Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2023-11-01
DOI
10.2217/fon-2022-0879
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Subtypes of EGFR and HER2 mutant metastatic NSCLC influence response to immune checkpoint inhibitors
- (2021) Sally CM. Lau et al. Clinical Lung Cancer
- Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
- (2021) Shuo Yang et al. Translational Lung Cancer Research
- Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non–small cell lung cancer
- (2021) Yasuto Yoneshima et al. Journal of Thoracic Oncology
- Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations
- (2021) Felix C. Saalfeld et al. Journal of Thoracic Oncology
- EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
- (2021) Alex Friedlaender et al. Nature Reviews Clinical Oncology
- Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
- (2020) Florian Guisier et al. Journal of Thoracic Oncology
- Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
- (2020) Fei Xu et al. Thoracic Cancer
- Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy.
- (2020) Guo-Chun Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
- (2020) Kaiyan Chen et al. Thoracic Cancer
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- (2019) T Bachelot et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
- (2019) Jean-Bernard Auliac et al. ADVANCES IN THERAPY
- Progress in research on paclitaxel and tumor immunotherapy
- (2019) Linyan Zhu et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma
- (2019) Wenfeng Fang et al. ONCOLOGIST
- Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
- (2018) Yan Wang et al. BMC CANCER
- Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
- (2018) Masayuki Takeda et al. Oncotarget
- PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.
- (2018) Wei-Chu Victoria Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301
- (2016) Shinya Sakata et al. LUNG CANCER
- Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
- (2016) Juliana Eng et al. LUNG CANCER
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started